Bridge-to-transplant vs. destination therapy — how age, comorbidity burden, and evolving candidacy shape the LVAD strategy decision
Before any decision is made about an LVAD, a multidisciplinary heart-transplant team must answer a single upstream question: is this patient, now or in the foreseeable future, a viable candidate for heart transplantation? The answer to that question — not the severity of heart failure alone — is what ultimately separates a bridge-to-transplant strategy from destination therapy.
Candidacy assessment is a structured, multidisciplinary process — cardiology, cardiac surgery, social work, psychiatry, nutrition, and financial counseling all weigh in. Core domains include:
• Age and physiologic reserve: chronological age matters less than functional age; a fit 70-year-old may be a better candidate than a frail 60-year-old • End-organ function: renal function (eGFR), hepatic congestion, pulmonary hypertension and pulmonary vascular resistance (fixed PVR is a hard contraindication without a bridge strategy) • Frailty: gait speed, grip strength, sarcopenia, and cognitive assessment predict post-transplant recovery independent of age • Psychosocial support: reliable caregiver support, adherence history, substance-use status, and health literacy — immunosuppression is unforgiving of non-adherence • Active malignancy or infection: generally requires a disease-free interval before listing • Obesity and cachexia: both extremes of body composition raise perioperative risk and are frequently addressed before final listing
No single factor is disqualifying in isolation; the team weighs the whole picture, and initial "unlikely" assessments are sometimes revisited after optimization.
Relative and absolute contraindications differ across transplant centers, which is why the same patient can be declined at one program and accepted at another after multidisciplinary review — candidacy assessment is a judgment process, not a fixed checklist.
LVAD implantation is a major cardiac surgery with lifelong implications, so the intended purpose of the device is decided (as much as possible) before the pump goes in. A patient assessed as a likely transplant candidate is typically implanted with a bridge-to-transplant intent — device selection, anticoagulation targets, and follow-up cadence are all oriented around eventual explant at transplant. A patient assessed as an unlikely candidate is instead counseled toward destination therapy, where the conversation shifts to lifelong device management, driveline care, and end-of-life planning around the pump itself.
The practical reality is messier than a binary split: many patients fall into a borderline zone where candidacy is uncertain at the time LVAD support becomes clinically necessary. This is where the "bridge to decision" concept becomes essential — covered in Stage 5.
In bridge-to-transplant (BTT), the LVAD is implanted with the explicit intent of keeping an eligible patient alive and clinically optimized until a matching donor heart becomes available. The pump is a means to an end — hemodynamic support that buys time, reverses secondary organ damage, and improves the patient's condition so that transplant surgery itself becomes lower-risk.
Advanced heart failure before LVAD implant is often accompanied by low cardiac output, renal hypoperfusion, hepatic congestion, cachexia, and functional decline — all of which raise the risk of transplant surgery and worsen post-transplant outcomes. Restoring near-normal cardiac output with an LVAD typically:
• Improves renal and hepatic function as forward flow and venous congestion normalize • Allows nutritional rehabilitation and reconditioning through cardiac rehab • Reduces pulmonary artery pressures over time, which can convert a borderline-fixed pulmonary vascular resistance into a transplantable range • Gets patients out of the ICU and back into an ambulatory, higher-functioning state — improving surgical candidacy for the eventual transplant operation
The device essentially converts an unstable, deteriorating patient into a stable outpatient who can wait — sometimes for a year or more — for the right organ match.
The UNOS heart allocation system uses a six-tier status framework; hemodynamically stable, ambulatory LVAD patients typically sit in an intermediate status tier, while patients with device complications (infection, pump thrombosis, arrhythmia) can be upgraded to a higher-urgency status.
Once bridged, patients enter a period of active waitlist management: routine echocardiography and right-heart catheterization to confirm favorable hemodynamics, driveline-site care to prevent infection, INR/anticoagulation monitoring to balance thrombosis versus bleeding risk, and regular reassessment of transplant eligibility. Some patients improve enough on device support that transplant urgency decreases; a minority deteriorate or develop device complications that either accelerate their listing status or, in rare cases, prompt reconsideration of goals of care.
When a matching donor heart is identified, the LVAD is explanted at the time of transplant surgery — the bridge is complete and the destination becomes a new heart rather than the pump itself.
When a patient is assessed as unlikely to ever become a transplant candidate — commonly due to advanced age, irreversible comorbidities, or contraindications that cannot be corrected — the LVAD is implanted as destination therapy (DT): permanent mechanical circulatory support with no donor-heart endpoint. The pump itself becomes the long-term treatment for the patient's heart failure.
Destination therapy has a clear evidence lineage. The REMATCH trial (2001) randomized inoperable heart-failure patients to a first-generation pulsatile LVAD versus optimal medical therapy and showed a significant survival benefit with the device — establishing, for the first time, that a permanently implanted pump could outperform medications alone in patients who were not transplant candidates. Since then, device technology has advanced through axial-flow pumps to today's magnetically levitated centrifugal-flow pumps, each generation reducing pump thrombosis, stroke, and device malfunction rates while improving durability.
Because a DT pump has no planned removal date, durability and long-term complication rates matter enormously — a device that performs adequately for two years as a bridge may be inadequate as a decade-plus destination.
The FDA approved continuous-flow LVADs for the destination-therapy indication in 2010, and by the early 2020s destination therapy accounted for roughly half or more of all LVAD implants in the US — a reflection of both an aging heart-failure population and growing confidence in device durability.
DT patients and caregivers take on a different set of lifelong responsibilities than BTT patients awaiting transplant: permanent anticoagulation management, daily driveline dressing changes to prevent infection, carrying external battery packs and a controller at all times, and structured emergency protocols for alarms or power loss. Because there is no future transplant to eventually resolve these burdens, DT decision-making places heavy weight on the patient's and family's capacity and willingness to sustain this regimen indefinitely — which is exactly why psychosocial and caregiver-support evaluation, discussed in Stage 1, matters just as much for DT candidates as for BTT candidates.
Goals-of-care conversations, including device deactivation planning for end-of-life scenarios, are typically introduced at the time of DT implant — a discussion that is structurally different from BTT, where the "exit" is transplant rather than device deactivation.
Randomized and registry evidence consistently shows that LVAD support — whether intended as a bridge or as destination therapy — improves survival and quality of life compared with optimal medical management alone in appropriately selected advanced heart-failure patients. But the two pathways diverge in an important way: BTT patients have a defined exit (transplant), while DT patients carry device-related risk indefinitely, since there is no transplant to eventually relieve that burden.
Whether bridged to transplant or implanted as destination therapy, LVAD recipients typically experience dramatic improvement in functional capacity: NYHA class often improves from IIIB/IV to I/II, six-minute walk distance increases substantially, and validated quality-of-life instruments (like the Kansas City Cardiomyopathy Questionnaire) show large gains within the first few months of support. This functional recovery is what allows BTT patients to safely wait for transplant and what makes DT a viable long-term strategy rather than a stopgap.
Survival benefit versus medical therapy alone is well established for both intents in appropriately selected patients — the REMATCH and later trials showed this for DT, and BTT patients essentially inherit the survival benefit of transplant itself once bridged successfully to surgery.
The key outcomes distinction between the two strategies is time horizon of device-related risk. A BTT patient's exposure to pump thrombosis, GI bleeding from acquired von Willebrand syndrome, driveline infection, and stroke is bounded by the wait time to transplant — once transplanted, most of that ongoing device risk disappears (replaced by transplant-specific risks like rejection and immunosuppression-related infection/malignancy). A DT patient's exposure to those same device-related complications is open-ended, accumulating for as long as the pump remains in place, which for younger DT patients or those who outlive expectations can mean many years.
This is precisely why DT candidacy decisions weigh caregiver support, adherence capacity, and patient goals so heavily — the risk-benefit calculus of "indefinite device life with device-related complication risk" is different from "device life bounded by an expected transplant."
Registry data consistently show that adverse-event rates per patient-year (bleeding, infection, thrombosis) are broadly similar between BTT and DT LVAD cohorts on the same device platform — the difference is not event rate but cumulative exposure time, since DT patients carry that per-year risk for an unbounded duration.
Not every patient arrives at the LVAD decision with a clean BTT-or-DT label already settled. Some patients need urgent mechanical support before the heart team has finished evaluating transplant candidacy; others start in one category and shift to the other as their clinical, renal, frailty, or psychosocial status evolves. "Bridge to decision" — sometimes framed as "bridge to candidacy" — is the honest acknowledgment that this classification can be provisional.
Cardiogenic shock and rapidly decompensating heart failure do not always wait for a completed transplant workup. A patient in INTERMACS profile 1 or 2 (critical cardiogenic shock or progressive decline on inotropes) may need an LVAD urgently to survive the next 24–72 hours, well before psychosocial evaluation, malignancy screening, or a full renal/hepatic recovery trial can be completed. In these cases, the device is implanted with an open-ended "bridge to decision" intent: keep the patient alive and hemodynamically stable, then complete the candidacy evaluation once the acute crisis has resolved.
This differs from a planned BTT implant, where candidacy is typically confirmed before surgery, and from a planned DT implant, where non-candidacy is typically already established.
Once stabilized on device support, a patient's trajectory can move toward either pathway:
• Toward BTT: renal and hepatic function often improve substantially once forward flow is restored, sometimes converting a previously borderline candidate into a listable one; nutritional and functional rehabilitation can resolve frailty concerns; psychosocial support structures can be arranged that were not in place at the time of emergency implant • Toward DT: a patient may fail to recover renal or hepatic function despite adequate device flow; new comorbidities (stroke, malignancy) may emerge during the wait; or the patient/family may determine, after living with the device, that they prefer not to pursue transplant
Because of this fluidity, most programs build periodic re-evaluation into LVAD follow-up regardless of the original implant intent — candidacy is treated as a status to be monitored, not a one-time verdict.
"Bridge to decision" is not a separate device or surgical technique — it is a framing of intent. The same LVAD hardware supports BTT, DT, and bridge-to-decision patients; what differs is the plan for reassessment and the destination the team and patient are working toward.